logo
Plus   Neg
Share
Email

Pfizer Reaches Global Agreement With AbbVie; To Withdraw Pending Litigation

Pfizer Inc. (PFE) said Friday that it has signed licensing agreements with AbbVie Inc. (ABBV), resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar.

Pfizer noted that all litigation pending between the parties will be withdrawn. The financial details of the agreements are confidential.

Under the terms of the agreements, AbbVie has granted Pfizer a non-exclusive patent license for the use and sale of Pfizer's proposed adalimumab biosimilar for many countries around the world.

Pfizer may launch its adalimumab biosimilar upon approval by the European Medicines Agency in Europe. In the U.S., the license period will begin on November 20, 2023.

"This settlement will facilitate patient access to Pfizer's proposed adalimumab biosimilar which we expect to be an important addition to our broad portfolio of biosimilar medicines," said Richard Blackburn, Global President, Inflammation and Immunology at Pfizer.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Biogen Inc. are falling almost 28 percent in Thursday's trading after the company and Japanese drugmaker Eisai Co. said they will discontinue two late-stage trials for their experimental Alzheimer's drug, Aducanumab. The two Phase 3 trials, ENGAGE and EMERGE, are multi-center, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate Aducanumab. The European Union on Wednesday ordered Alphabet Inc.'s Google to pay an antitrust fine of 1.49 billion euros for abusing its dominant position in the online search advertising intermediation market by preventing competition. This is the third antitrust fine by the EU against Google and it represents 1.29 percent of the tech giant's turnover in 2018. Shares of BMW Group declined around 5 percent in German trading after the auto giant reported Wednesday weak profit in its fiscal year 2018, despite a 0.1 percent growth in Automotive revenues with higher deliveries. Looking ahead for fiscal 2019, the company expects Group profit before tax will be well below the previous year's level. BMW said it is confident of volume growth in Automotive unit.
Follow RTT